Search Within

Gregory J Riely

  1. "Michael Offin"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (17)
  3. Review (1)
Groups
  1. Department of Medicine (40)
  2. Hematology-Oncology Fellows (40)
  3. Solid Tumor Oncology Division (40)
  4. Thoracic Oncology (40)
  5. Weinberg Fellows (40)
  6. GSK Faculty (33)

More Groups

People
  1. Michael Offin (40)
  2. Mark Kris (28)
  3. Alexander Drilon (24)
  4. Charles Rudin (24)
  5. Bob Li (22)
  6. Helena Yu (21)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (1)
  6. 2020 (6)

More Years

Publications
  1. Journal of Thoracic Oncology (11)
  2. Journal of Clinical Oncology (8)
  3. Clinical Cancer Research (5)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (3)
  6. Acta Oncologica (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Elsevier Inc. (11)
  3. American Association for Cancer Research (6)
  4. Oxford University Press (4)
  5. Nature Publishing Group (2)
  6. Elsevier Ireland Ltd. (1)

More Publishers

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC—A brief report
    Journal Article

    Riely, G. J.; Ahn, M. J.; Clarke, J. M.; Dagogo-Jack, I.; Esper, R.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma
    Meeting Abstract

    Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A plain language summary of the PHAROS study: The combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
    Review

    Riely, G. J.; Smit, E. F.; Ahn, M. J.; Felip, E.; Ramalingam, S. S.; Tsao, A.; Johnson, M.; Gelsomino, F.; Esper, R.; Nadal, E.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Brain metastases in patients with fusion-positive lung cancers
    Meeting Abstract

    Sui, J. S.; Chen, M. F.; Wilcox, J.; Yang, S. R.; Li, B. T.; Riely, G. J.; Offin, M.; Yu, H. A.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAF (V600E)) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study
    Meeting Abstract

    Riely, G. J.; Smit, E. F.; Ahn, M. J.; Felip, E.; Ramalingam, S. S.; Tsao, A. S.; Johnson, M. L.; Gelsomino, F.; Esper, R. M.; Nadal, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save